Therapy of IgA nephropathy with mycophenolate mofetil - Report of 3 cases

Clinical Nephrology

Volumn 61, Issue 3, 2004, Pages 207-212

  Bergner, R ^a   Hoffman, M ^a   Brass, H ^a   Uppenkamp, M ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Creatinine; IgA nephropathy; Mycophenolate mofetil; Proteinuria

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; PNEUMONIA; PROTEINURIA;

EID: 1642338811     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP61207     Document Type: Article

References (34)

1. Ballardie FW, Roberts ISD 2002 Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13: 142-148
2. Bennett WM, Walker RG, Kincaid-Smith P 1989 Treatment of IgA nephropathy with eicosapentanoic acid (EPA): A two-year prospective trial. Clin Nephrol 31: 128-131
3. Briggs WA, Choi MJ, Scheel PJ 1998 Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31: 213-217
4. Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Ji YL, Lau CS, Wong AKM, Tong MKL, Chan KW, Lai KN 2000 Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343: 1156-1162
5. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE 1994 A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331: 1194-1199
6. Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC 1999 The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 10: 1772-1777
7. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA 1999 Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10: 833-839
8. D'Amico G, Colasanti G, Barbiano di Belgioioso G, Fellin G, Ragni A, Egidi F, Radaelli L, Fogazzi G, Ponticelli C, Minetti L 1987 Long-term follow-up of IgA mesangial nephropathy: Clinico-histological study in 374 patients. Semin Nephrol 7: 355-358
9. Frimat L, Briancon S, Hestin D, Aymard B, Renoult E, Huu TC, Kessler M 1997 IgA nephropathy: Prognostic classification of end-stage renal failure. L'Association des Nephrologues de l'Est. Nephrol Dial Transplant 12: 2569-2575
10. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W 1999 Mycophenolate mofetil for the treatment of systemic lupus erythematodes: an open pilot trial. Lupus 8: 1-6
11. Glicklich D, Acharaya A 1998 Mycophenolate mofetil for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 32: 318-322
12. Goumenos D, Ahuja M, Shortland JR, Brown CB 1995 Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol Dial Transplant 10: 1173-1181
13. Grande JP, Walker HJ, Holub BJ, Warner GM, Keller DM, Haugen JD, Donadio JV, Dousa TP 2000 Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 57: 1027-1040
14. Haas M 1997 Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 29: 829-842
15. Hwang YC, Lee TW, Kim MJ, Ynag MH, Ihm CG 2001 Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone. Korean J Intern Med 16: 105-109
16. Ibels LS, Gyory AZ, Caterson RJ, Pollock CA, Mahony JF, Waugh DA, Roger SD, Coulshed S 1997 Primary IgA nephropathy: Natural history and factors of importance in the progression of renal impairment. Kidney Int 61 (Suppl): 67-70
17. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S 1996 Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 72: 237-242
18. Maes BD, Evenepoel P, Kuypers D, Messiaen Th, Vanrenterghem Y 2001 A prospective placebo-controlled randomized single-centre study of mycophenolate mofetil treatment for IGA nephropathy: Lack of clinical efficacy after two years. Abstract A 0599: ASN
19. McIntyre CW, Fluck RJ, Lambie SH 2001 Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric (???) change: An effective treatment. Clin Nephrol 56: 193-198
20. Mera J, Uchida S, Nagase M 2000 Clinicopathologic study on prognostic markers in IgA nephropathy. Nephron 84: 148-157
21. Nowak R, Birck R, van der Woude FJ 1997 Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 349: 774
22. Nowak R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ 1999 Mycophenolate mofetil for maintenance therapy of Wegener granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10 1965-1971
23. Perna A, Remuzzi G 1996 Abnormal permeability to proteins and glomerular lesion: A meta-analysis of experimental and human studies. Am J Kidney Dis 27: 34-41
24. Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, Bjorkhem I, Bergstrom J 1994 Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin Nephrol 41: 183-190
25. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F 1999 Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353: 883-887
26. Radford MG, Donadio JV, Bergstralh EJ, Grande JP 1997 Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199-207
27. Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M, Piccoli G, Sena LM 2000 Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 15: 833-835
28. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A 1999 Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10: 1542-1549
29. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi C 1998 Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int 53: 1209-1216
30. Schiele J, Nowak R, Julian BA, van der Woude FJ 1999 Treatment of immunoglobulin A nephropathy. Ann Med Interne 150: 127-136
31. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y 2000 Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35: 194-201
32. Tamura S, Ueki K, Ideura H, Tsukada Y, Maezawa A. Kawai H, Wakamatsu R, Yano S, Nojima Y, Naruse T 2001 Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 55: 192-195
33. Tsuruya K, Harada A, Hirakata H, Mitsuki K, Johko T, Kondoh H, Takechi S, Fujishima M 2000 Combination therapy using prednisolone and cyclophosphamide slows the progression of moderatly advanced IgA nephropathy. Clin Nephrol 53: 1-9
34. Xiangmei C, Jie W, Yanping Z, Shuwen L, Li T 2001 72-week follow-up study of effects of mycophenolate mofetil on IgA nephropathy. Abstract A 0353: ASN